Pharma company Valiant Laboratories to go public on September 27
Pharmaceutical company Valiant Laboratories has fixed the price band for its initial public offering (IPO) at Rs 133-140 per share. The offer will open for subscription on September 27 and close on October 3.
The firm is planning to raise Rs 152.46 crore via the IPO at the upper price band. The offer consists of only a fresh issue of 1.09 crore equity shares by the company.
Investors can bid for a minimum of 105 equity shares and in multiples of 105 shares thereafter. The minimum application size for retail investors would be Rs 14,700 (105 shares) and the maximum investment would be Rs 1,91,100 (1,365 shares), as they cannot exceed their investment limit beyond Rs 2 lakh in the IPO.
High networth individuals, with an investment limit of Rs 2 lakh to Rs 10 lakh, can invest a minimum of Rs 2,05,800 (for 1,470 shares) and a maximum of Rs 9,99,600 (for 7,140 shares), at the upper price band.
The company will use the net proceeds from the fresh issue to fund the expenditure for setting up a manufacturing facility for speciality chemicals (ketene and diketene derivatives products) in Bharuch, Gujarat owned by its subsidiary, Valiant Advanced Sciences. The remaining fresh issue money will be utilised for working capital requirements and general corporate purposes.
Valiant Laboratories is a Mumbai-based active pharmaceutical ingredient (API) and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Promoters Shantilal Shivji Vora and Santosh Shantilal Vora hold 10.01 percent stake each in the company.
Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
This is supposed to be the last amongst 13 public issues in the current month. Others included Manoj Vaibhav Gems N Jewellers, Sai Silks (Kalamandir), Signature Global, Yatra Online, Zaggle Prepaid Ocean Services, SAMHI Hotels, RR Kabel, EMS, Jupiter Life Line Hospitals, and Ratnaveer Precision Engineering.
- 22 Sep
Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.
- 21 Sep
Signature Global IPO Subscription Update
Signature Global's IPO has received decent response from investors so far, with HNIs and retail investors being the most aggressive bidders. However, analysts advise investors to be cautious due to the company's history of losses and the fluctuating nature of the real estate industry.